This study investigated if catheter-based renal denervation can manage hypertension without medication.

They found that patients that underwent renal denervation had reduced blood pressure measures over three months.

This study investigated the effects of diet and physical activity in preventing or delaying type 2 diabetes (T2D), and its complications, in people at high risk of developing T2D. It was determined that diet and/or physical activity reduces or delays the development of T2D in these people.

This study investigated if reducing salt intake and/or using the DASH diet had any effect on blood pressure levels in patients with pre- or stage 1 hypertension.

They found that the combination of reducing salt and adhering to the DASH diet reduced blood pressure.         

The main objective of this trial is to determine the effectiveness and durability of a combined group of drugs (exenatide [Byetta], pioglitazone [Actos] and metformin [Glucophage]) compared to standard treatment in type 2 diabetes. The main outcome to be measured will be the change in HbA1c (average blood glucose over 3 months).

This study compared the effects of two different diets in people with type 2 diabetes (T2D). It was determined that a low carbohydrate, high unsaturated fat and low saturated fat diet (LC) achieved the same weight loss and reductions in HbA1c (average blood glucose over the last 3 months) as a high carbohydrate/low fat diet (HC). It was also found that the LC diet reduced the need for diabetes medications and changes in blood glucose levels (glycemic variability) more than the HC diet. 

This study investigated if self-monitoring of blood pressure effectively manages hypertension. They found that self-monitoring lowered blood pressure when combined with co-interventions.

The main objective of this trial is to determine whether islet cell transplantation (ICT) using anti-thymocyte globulin (ATG) is a safe and effective treatment for type I diabetes. The main outcome to be measured is number of patients who no longer need insulin therapy following transplantation. This trial is being held in Duarte, California. 

This study determined the safety and effectiveness of ertugliflozin (Steglatro) as a single therapy for adults with poorly controlled type 2 diabetes despite diet and exercise. This study concluded that 1 year of ertugliflozin improved glycemic (blood sugar) control and reduced body weight and blood pressure, but increased genital infections.

This phase 3 clinical trial will investigate the effectiveness and safety of oral sotagliflozin. The primary outcome will be reduction in HbA1c (average blood glucose over the last 3 months). This trial will take place in the United States and Canada.

This study examined the effects of dapagliflozin (Farxiga) and exenatide (Byetta) in different groups of people with type 2 diabetes (T2D). It was determined that a combination of the drugs reduces weight, blood pressure, and triglycerides (type of fat found in the blood) more than either alone. The greatest reductions were seen in people who started with high weight, high blood pressure, and normal triglyceride levels.